What Has Been the Growth of the Perjeta Pertuzumab Market So Far?
The perjeta pertuzumab market has seen considerable growth due to a variety of factors.
• In the past few years, the market size of Perjeta (Pertuzumab) has expanded swiftly. It is projected to rise from $935.92 million in 2024 to $1,084.80 million in 2025, boasting a compound annual growth rate (CAGR) of 15.9%.
Several factors have attributed to this expansion during the historical period, such as increased usage in oncology, a surge in demand for Antibody-Drug Conjugates (ADCs), preference for more targeted and less harmful treatments, spike in inorganic growth, and amplified demand for individualized medicine.
How Will the Perjeta Pertuzumab Market Size?
The perjeta pertuzumab market is expected to maintain its strong growth trajectory in upcoming years.
• Over the coming years, the Perjeta (pertuzumab) market is anticipated to witness a swift upsurge. The market is predicted to expand to $1,932.66 million in 2029 with a compound annual growth rate (CAGR) of 15.5%.
This anticipated growth for the forecast period can be traced back to several factors including an increasing number of breast cancer cases, growing interest in Antibody-Drug Conjugates (ADCs) for blood-related malignancies, a swell in cancer incidences and medical needs that are yet to be met, as well as a rise in the pharmaceutical industry's research and development initiatives for cancer immunotherapy. Key trends expected to influence the forecast period involve the integration of biosimilars in oncology, the rise in biosimilars and generics, innovative strides in drug formulation, progress in research on cancer immunotherapy, and the prominence of combination therapies.
Which Drivers Are Accelerating Growth In The Perjeta Pertuzumab Market?
The escalating prevalence of breast cancer is anticipated to stimulate the expansion of the Perjeta (pertuzumab) market in the future. Breast cancer signifies a condition in which harmful cells proliferate in the breast tissue, generally stemming from the ducts or lobules. The escalating prevalence of breast cancer can be linked with changes in lifestyle like an increase in obesity and inactive routines, along with better early detection via prevalent screening programs. Perjeta (pertuzumab) is employed in treating HER2-positive breast cancer by aiming at the HER2 receptor and it's typically fused with trastuzumab and chemotherapy to enhance treatment results. For instance, in October 2023, the Ray of Light Wales, a UK-based non-profit charity, projected that the number of individuals in the UK surviving post a breast cancer diagnosis will be around 600,000 and it is anticipated to increase to 1.2 million by 2030. Consequently, the escalating prevalence of breast cancer is fuelling the expansion of the herceptin biosimilars market.
What Key Areas Define The Segmentation Of The Global Perjeta Pertuzumab Market?
The perjeta (pertuzumab) market covered in this report is segmented –
1) By Type: Human source, Animal source
2) By Product: Monoclonal Antibody, Biologic Drug
3) By Indication: Early Breast Cancer, Metastatic Breast Cancer
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Pre-Book The Perjeta Pertuzumab Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Perjeta Pertuzumab Market?
A prominent trend in the Perjeta (pertuzumab) market is the emphasis on creating technologically superior solutions, such as subcutaneous combination therapies, to enhance patient results and treatment convenience. Subcutaneous combination therapies involve using two or more drugs in one injection under the skin for treating specific conditions. For example, in November 2023, Chugai Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, introduced Phesgo, a subcutaneous combo treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This revolutionary subcutaneous administration solution combines the monoclonal antibodies pertuzumab and trastuzumab with vorhyaluronidase alfa, enabling the treatment to be administered within 5 to 8 minutes, significantly decreasing time compared to traditional intravenous infusions. Phesgo is suggested for patients with advanced or recurrent HER2-positive colorectal cancer, marking the first subcutaneous option for this condition.
Who Are the Key Players In The Perjeta Pertuzumab Market?
Major companies operating in the perjeta (pertuzumab) market include:
• Roche Holding AG
What Is The Most Dominant Region In The Perjeta Pertuzumab Market?
North America was the largest region in the perjeta (pertuzumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
